Zepbound and Gallstones: What the Trial Data Shows, What the Mechanism Is, and When to Call Your Provider

Direct answer (40-60 words)

In the SURMOUNT-1 trial, gallstones (cholelithiasis) occurred in 1.1% of tirzepatide patients vs. 1.0% of placebo patients, and acute cholecystitis in 0.7% vs. 0.2%. The risk is real but small, driven mostly by rapid weight loss rather than the medication itself. Existing gallstones are not an automatic contraindication to Zepbound.

Table of contents

1. The 30-second answer
2. What gallstones are and why fast weight loss raises risk
3. The clinical trial numbers for tirzepatide
4. Why GLP-1 medications increase gallbladder risk specifically
5. Existing gallstones: when Zepbound is still appropriate
6. Symptoms that mean a gallstone is moving (and what to do)
7. The protocol to lower gallbladder risk while on tirzepatide
8. Surgery, ursodiol, and other treatment options
9. Dose titration and gallbladder safety
10. FAQ

What gallstones are and why fast weight loss raises risk

Gallstones are hardened deposits of cholesterol or bilirubin that form in the gallbladder, a small pear-shaped organ under the liver that stores bile. Bile is a digestive fluid the liver produces to help break down dietary fat. When the chemistry of bile shifts (more cholesterol, less bile salts, less lecithin to keep things dissolved), cholesterol crystals can precipitate and aggregate into stones.

About 80% of gallstones in the United States are cholesterol stones. The remaining 20% are pigment stones made of bilirubin, more common in chronic hemolysis or liver disease.

Three main risk factors for gallstone formation:

• Female sex. Women form gallstones at about twice the rate of men, particularly during reproductive years.
• Obesity. Higher BMI is associated with cholesterol-supersaturated bile.
• Rapid weight loss. Losing more than about 1.5% of body weight per week sharply increases gallstone risk.

The third risk is the one that matters for patients on Zepbound. The standard textbook reference is Liddle et al., Annals of Internal Medicine, 1989, which found that 25% of patients on a very-low-calorie diet (VLCD) developed gallstones over 8 weeks of rapid weight loss, with 6% developing symptoms requiring intervention.

The mechanism: when fat stores break down faster than the liver can clear cholesterol from bile, the bile becomes supersaturated. Combined with reduced gallbladder contractility (because less fat is hitting the duodenum to trigger contractions), bile sits in the gallbladder for longer. Stagnant, cholesterol-rich bile is gallstone-formation conditions.

Tirzepatide produces clinically meaningful weight loss (around 20% body weight at the highest dose over 72 weeks in SURMOUNT-1). That's slower than a VLCD, which is why the absolute risk is lower than the historical 25%, but it's faster than dietary-only weight loss, which is why the risk is higher than placebo.

The clinical trial numbers for tirzepatide

The most informative data comes from SURMOUNT-1, the main obesity trial for tirzepatide.

Outcome	Tirzepatide (any dose)	Placebo
Cholelithiasis (gallstones)	1.1%	1.0%
Acute cholecystitis (inflamed gallbladder)	0.7%	0.2%
Cholecystectomy (gallbladder removal)	0.2%	<0.1%
Biliary colic (gallstone pain without infection)	0.6%	0.2%

The signal for cholecystitis is more clear than for gallstones themselves. In other words, tirzepatide may not produce many more gallstones than placebo, but it appears to produce more cases where existing or new gallstones become symptomatic and inflamed.

Comparable data from SURPASS (the diabetes program) showed similar patterns at lower absolute rates, likely because diabetes patients in those trials had less weight loss on average.

For semaglutide, the parallel data from STEP 1:

• Cholelithiasis: 2.5% on semaglutide 2.4 mg vs. 1.0% on placebo
• Cholecystitis: 0.6% vs. 0.2%

The semaglutide signal for stone formation is somewhat stronger than tirzepatide's, possibly because of differences in gastric emptying and gallbladder motility between the two drugs.

For comparison, the general U.S. adult population has a roughly 10 to 15% prevalence of gallstones (most never causing symptoms). The annual incidence of new symptomatic gallstones in the general population is about 1 to 2%.

So tirzepatide raises the annual cholecystitis risk from a baseline of around 0.2% to around 0.7%. The relative increase is meaningful (3-fold), but the absolute numbers stay small.

Why GLP-1 medications increase gallbladder risk specifically

Three mechanisms contribute, each with a different timeline.

Mechanism 1: Rapid weight loss. As discussed above, this is the main driver. Patients losing 10% or more of body weight over a few months have measurably higher gallstone risk. Tirzepatide produces this kind of weight loss in most patients.

Mechanism 2: Reduced gallbladder motility. GLP-1 receptors are present on gallbladder smooth muscle. Activating them slows gallbladder emptying. Bile pools in the gallbladder longer, raising the risk of crystallization. This effect is independent of weight loss; it's a direct pharmacologic effect.

Mechanism 3: Reduced fat intake. Patients on tirzepatide typically eat less, including less dietary fat. The gallbladder normally contracts in response to fat in the duodenum (mediated by cholecystokinin). Less dietary fat means fewer contractions, which means more bile stasis.

The three mechanisms work together. The patient on Zepbound who has gone from a 2,500-calorie diet to a 1,500-calorie diet, lost 35 lb, and reduced fat intake from 90 g/day to 50 g/day has all three risk factors stacked.

The pharmacologic effect (mechanism 2) is the only one that's specific to GLP-1 medications. The other two are shared with any rapid-weight-loss intervention, including bariatric surgery and VLCDs.

Existing gallstones: when Zepbound is still appropriate

Asymptomatic gallstones (also called "silent" or "incidental" gallstones) are common. About 80% of people with gallstones never develop symptoms. If your gallstones were found on imaging done for another reason and have never caused pain or other symptoms, you're in the asymptomatic category.

The clinical question: should asymptomatic gallstones disqualify you from Zepbound?

The answer in practice is usually no, but the conversation matters. Tirzepatide's prescribing information does not list asymptomatic cholelithiasis as a contraindication. The American Association of Clinical Endocrinology guidance on obesity pharmacotherapy notes that GLP-1 medications can be used in patients with known gallstones, with the caveat that providers should monitor for symptoms.

What changes the calculus toward "no, don't start Zepbound right now":

• Recent biliary colic episodes. A patient who had two episodes of right-upper-quadrant pain after fatty meals in the past 6 months should probably address the gallbladder first.
• Common bile duct stones (choledocholithiasis). These can cause pancreatitis or cholangitis. They need to be addressed before starting any rapid-weight-loss intervention.
• History of acute cholecystitis. Even one episode of cholecystitis is a strong relative contraindication to anything that raises the risk of another.
• Multiple risk factors stacked. Female, age over 50, family history of gallbladder disease, and known asymptomatic stones is a risk profile where ursodiol prophylaxis or cholecystectomy before starting tirzepatide may be discussed.

What doesn't change the calculus:

• One small asymptomatic stone discovered incidentally. Most providers will start Zepbound with monitoring instructions.
• A history of gallbladder polyps without stones. Polyps don't directly raise stone risk.
• Prior cholecystectomy. Patients who have already had their gallbladder removed cannot develop gallstones (they have nowhere to form). Tirzepatide is generally safe in post-cholecystectomy patients.

For more on related side effects, see related guide and related guide.

Symptoms that mean a gallstone is moving (and what to do)

Most gallstones cause no symptoms. The ones that do follow a recognizable pattern.

Biliary colic (the classic gallstone attack):

• Sudden, severe pain in the upper right abdomen or upper middle abdomen
• Often radiates to the right shoulder blade or between the shoulder blades
• Triggered by a fatty meal, sometimes 30 to 60 minutes after eating
• Lasts 30 minutes to several hours
• Resolves spontaneously when the stone passes back into the gallbladder
• Often accompanied by nausea or vomiting

If this happens once and resolves, contact your provider within 24 to 48 hours. Don't take the next dose of Zepbound until you've talked to a clinician.

Acute cholecystitis (the gallbladder is inflamed because a stone is stuck):

• Persistent right-upper-quadrant pain (not resolving in a few hours)
• Fever or chills
• Tenderness when the right upper abdomen is pressed
• Nausea and vomiting that doesn't resolve
• Yellowing of the skin or eyes (rare, but a red flag)

This is an emergency. Go to an ER. Cholecystitis usually requires intravenous antibiotics and, often, surgery within 24 to 72 hours.

Choledocholithiasis (a stone is stuck in the common bile duct):

• Severe abdominal pain
• Jaundice (yellow skin or eyes)
• Dark urine
• Pale (clay-colored) stools
• Fever (if cholangitis develops)

Also an emergency. ERCP (endoscopic retrograde cholangiopancreatography) is usually needed to remove the stone.

Pancreatitis from a gallstone:

• Severe upper abdominal pain that radiates to the back
• Persistent nausea and vomiting
• Pain worse when lying flat
• Pain partially relieved by leaning forward

Also an emergency. Tirzepatide carries a small independent pancreatitis risk, and gallstone pancreatitis can be confused for it.

The rule: any new severe right-upper-quadrant pain on a GLP-1 medication should be evaluated. Don't try to ride it out.

The protocol to lower gallbladder risk while on tirzepatide

The interventions below are based on the same logic that's used for VLCDs and bariatric surgery patients.

1. Slow weight loss when possible. The faster the weight loss, the higher the risk. Most providers won't compromise efficacy by purposely slowing tirzepatide, but they may extend titration steps or hold a dose longer if a patient is losing more than 1.5% of body weight per week.

2. Maintain modest dietary fat intake. Counterintuitively, eating some fat at every meal (15 to 30 g) helps the gallbladder contract regularly, reducing bile stasis. Very-low-fat diets are worse for gallbladder health than moderate-fat diets in this setting.

3. Stay well-hydrated. Dehydration concentrates bile. Aim for clear or pale-yellow urine. On a GLP-1, this often means 80 to 100 oz of fluid per day.

4. Consider ursodiol (UDCA) prophylaxis. Ursodeoxycholic acid is an FDA-approved bile acid that reduces cholesterol saturation in bile. It can prevent gallstone formation during rapid weight loss. The standard dosing for prevention is 300 mg twice daily during active weight loss. Ursodiol is well-tolerated and inexpensive (about $30 to $80 per month). Some providers prescribe it routinely during the first 6 months of GLP-1 treatment, particularly for higher-risk patients. The evidence in tirzepatide patients is extrapolated from VLCD studies, where ursodiol reduced gallstone formation by about 80%.

5. Don't skip meals. Long fasting periods (over 14 hours) increase bile stasis. Eating something small every 4 to 6 hours during waking hours helps the gallbladder contract.

6. Adequate fiber intake. Fiber, particularly soluble fiber, may modestly lower gallstone risk. The mechanism isn't fully clear but may involve bile acid metabolism in the intestine.

The strongest of these interventions is ursodiol. If you have multiple gallstone risk factors, it's worth bringing up with your provider.

Surgery, ursodiol, and other treatment options

If gallstones become symptomatic, the standard treatments are:

Cholecystectomy (gallbladder removal): The definitive treatment for symptomatic gallstones. About 95% are done laparoscopically. Recovery is 1 to 2 weeks. Most patients tolerate the procedure well and can resume tirzepatide within 2 to 4 weeks of surgery, with provider clearance.

Ursodiol for symptomatic stones: Ursodiol can sometimes dissolve small (under 5 mm) cholesterol stones over 6 to 24 months. Recurrence rates are 50% within 5 years, so it's usually a temporary measure or reserved for patients who can't have surgery.

ERCP: For stones stuck in the common bile duct. Doesn't address the gallbladder itself; usually followed by elective cholecystectomy.

Watch and wait: For asymptomatic stones, no treatment is the standard recommendation. Monitoring with periodic imaging isn't routinely done.

After cholecystectomy, tirzepatide can be continued. Patients without a gallbladder cannot form new gallstones, which removes that specific risk. Some patients have post-cholecystectomy diarrhea (bile acid malabsorption) that can be exacerbated by GLP-1 effects on motility. Cholestyramine or colesevelam usually controls it.

Dose titration and gallbladder safety

The gallbladder risk follows the weight-loss rate, which follows the dose. Implications:

• 2.5 mg starter dose: Minimal weight loss, minimal incremental gallbladder risk
• 5 mg dose: 6 to 8% body weight loss over 6 months on average; modest risk increase
• 10 mg dose: 12 to 15% body weight loss; moderate risk increase
• 15 mg dose: 15 to 22% body weight loss; highest risk

Patients with risk factors who tolerate the medication well at 5 or 10 mg can sometimes hold at the lower dose to balance weight-loss benefits against gallbladder risk. The trade-off conversation is worth having with a provider.

If gallbladder symptoms develop during titration, the response is usually to hold the current dose, evaluate the symptoms (often with an abdominal ultrasound), and decide whether to continue, dose-reduce, or pause the medication. Routine "preventive" dose reduction in the absence of symptoms isn't typically recommended.

FAQ

Does Zepbound cause gallstones?

The trial data shows a small increase in gallstone-related events compared to placebo. The cholelithiasis rate is 1.1% vs. 1.0%, and the cholecystitis rate is 0.7% vs. 0.2%. The risk is mostly attributable to rapid weight loss rather than a direct effect of tirzepatide on stone formation.

How common is acute cholecystitis on Zepbound?

About 0.7% of patients in the SURMOUNT-1 trial. That's about 7 in 1,000 patients per year of treatment. Compared to a baseline of 0.2% on placebo, the relative risk is about 3-fold higher.

Can I take Zepbound if I already have gallstones?

Asymptomatic gallstones are usually not a contraindication. A history of biliary colic or cholecystitis is a stronger relative contraindication. Discuss your specific history with a provider.

Should I have my gallbladder removed before starting Zepbound?

Routine prophylactic cholecystectomy isn't recommended. Patients with symptomatic gallbladder disease may benefit from surgery before starting tirzepatide, but this is a case-by-case decision.

What is ursodiol and should I take it on Zepbound?

Ursodiol (ursodeoxycholic acid) is a bile acid that reduces cholesterol saturation in bile. Studies in VLCD patients show it reduces gallstone formation by about 80%. Some providers prescribe it routinely during the first 6 months of GLP-1 treatment for higher-risk patients.

Can I take Zepbound after my gallbladder has been removed?

Yes. Without a gallbladder, you can't form new gallstones. Tirzepatide is generally safe in post-cholecystectomy patients. Some have post-cholecystectomy diarrhea that may be worsened by GLP-1 effects on gut motility.

What does a gallstone attack feel like?

Severe pain in the upper right abdomen, often radiating to the right shoulder blade, typically triggered by a fatty meal and lasting 30 minutes to several hours. Often with nausea or vomiting.

Should I stop Zepbound if I have a gallstone attack?

Don't take the next dose until you've talked to a clinician. Most attacks are evaluated with an ultrasound; treatment depends on whether the stones are still present, whether the gallbladder is inflamed, and whether the patient wants to keep treating obesity.

Does compounded tirzepatide have the same gallbladder risk as Zepbound?

The active ingredient is the same, so the mechanism and risk profile are the same. There's no published trial data on compounded versions, but the pharmacology predicts equivalent risk.

Is the gallbladder risk worse with semaglutide or tirzepatide?

The trial data suggests a slightly higher gallstone signal with semaglutide than tirzepatide, though both are statistically significant compared to placebo. The differences are small and may reflect trial-specific factors rather than true differences between the drugs.

How much weight loss is "rapid" enough to raise gallbladder risk?

More than about 1.5% of body weight per week is the historical threshold from VLCD literature. Most tirzepatide patients lose 0.4 to 1.0% per week on average, which is below the threshold but adds up over months.

Will my insurance cover ursodiol if I'm on Zepbound?

Ursodiol is FDA-approved for several indications including gallstone dissolution and primary biliary cholangitis. Coverage for prevention during weight loss is variable; most insurance plans approve it with a documented clinical indication. The cash price is low even without coverage.

Author / review note

Reviewed by the FormBlends Medical Team. References include the SURMOUNT-1 trial publication (Jastreboff et al., NEJM, 2022), the tirzepatide prescribing information (Lilly, current revision), Liddle et al., Annals of Internal Medicine, 1989 (VLCD gallstone risk), and the American Gastroenterological Association guidance on gallstone management (2014, with updates).

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.